On illicit drug policies; methods of evaluation and comments on recent practices

Current Drug Abuse Reviews

Volumn 6, Issue 2, 2013, Pages 144-151

  Trovato, Giovanni ^a   Vezzani, Antonio ^b,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c EUROPEAN COMMISSION   (Belgium)

Author keywords

Drug policy evaluation; Illicit drugs; Social cost of drug abuse

Indexed keywords

COCAINE; ILLICIT DRUG; STREET DRUG;

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG ABUSE; DRUG COST; DRUG HARM INDEX; DRUG LEGISLATION; DRUG MARKETING; DRUG POLICY; DRUG PROGRAM; DRUG TRAFFIC; EUROPE; HARM REDUCTION; HUMAN; ILLICIT DRUG INDEX; MORTALITY; POLICY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REHABILITATION CARE; RISK FACTOR; SCORING SYSTEM; SEIZURE; TAX; UNCERTAINTY; ECONOMICS; EPIDEMIOLOGY; LEGISLATION AND JURISPRUDENCE; SUBSTANCE-RELATED DISORDERS;

COST OF ILLNESS; EUROPE; HUMANS; PUBLIC POLICY; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 84899408123     PISSN: 18744737     EISSN: 18744745     Source Type: Journal    
DOI: 10.2174/1874473706666131205152404     Document Type: Article

References (31)

1. Vander Laenen F, Vandam L, De Ruyer B. Studies on public drug expenditure in Europe: possibilities and limitations. UNODC, Bulletin on Narcotics 2008; 110: 27-44.
2. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Annual report 2012: the state of the drugs problem in Europe. Lisbon: EMCDDA, 2012.
3. Ritter A. Methods for comparing drug policies - the utility of composite Drug Harm Indexes. International Journal of Drug Polic 2009; 20(6): 475-479.
4. Rice DP. Cost of illness studies: what is good about them? Injury Prevention 2000; 6: 177-179.
5. Segel JE. Cost-of-Illness Studies-A Primer. Research Triangle Park, NC: RTI-UNC Center of Excellence in Health Promotion Economics; 2006.
6. Currie G, Kerfoot KD, Donaldson C, Macarthur C. Are cost of injury studies useful? Inj Prev 2000; 6: 175-176.
7. Moore TJ, Caulkins JP. How cost-of-illness studies can be made more useful for illicit drug policy analysis. Applied Health Economic and Health Policy 2006; 5(2): 75-85.
8. Byford S, Torgerson DJ, Raftery J. Cost of Illness Studies. BMJ 2000; 320(7245): 1335.
9. Plotnik RD. Applying Benefit Cost Analysis to Substance Use Prevention Programs. Int J Addict 1994; 29(3): 339-359.
10. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. Oxford University Press, New York; 1996.
11. Caulkins JP, Rydell CP, Everingham SS, Chiesa J, Bushway S. An Ounce of Prevention, A Pound of Uncertainty. The Cost-Effectiveness of School-Based Drug Prevention Programs. RAND, Drug Policy Research Center, Santa Monica, CA; 1999.
12. Attewell R, McFadden M. Measuring the benefits of drug law enforcement: the development of the Australian Federal Police Drug Harm Index. UNODC, Bulletin on Narcotics 2008; 110: 45-58
13. MacDonald Z, Tinsley L, Collingwood J, Jamieson P, Pudney S. Measuring the harm from illegal drugs using the Drug Harm Index. http://library.npia.police.uk/docs/hordsolr/rdsolr2405.pdf, Home Office Online Report 24/05; 2005.
14. United Nations Office On Drugs and Crime (UNODC). World Drug Report: 2005. Vienna: UNODC; 2005.
15. Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 2007; 369: 1047-1053.
16. Pacula RL, Hoorens S, Kilmer B, Burgdorf JR, Hunt P. Issues in estimating the economic cost of drug abuse in consuming nations. RAND Technical Report 3. Available from [Accessed 9th September 2013]:http://www.rand.org/pubs/technical_reports/TR709.html; 2009.
17. Kopp P, Fenoglio P. Calculating the Social Cost of Illicit Drugs. Methods and tool for estimating the social cost of the use of psychotropic substances. Council of Europe Publishing, Strasbourg, France; 2001.
18. Rydell C Peter and Everingham, Susan S. Controlling cocaine: Supply versus demand programs. RAND, Drug Policy Research Center, Santa Monica, CA, 331; 1994.
19. Miron JA. Drug War Crimes: The Consequences of Prohibition. Independent Institute, Oakland, CA; 2004.
20. Transform. Cost-effectiveness of Prohibition and Regulation of Drugs.Rolles S. (Eds.), Transform, Drug Policy Foundation, Bristol, UK; 2009.
21. Strang J, Babor T, Caulkins J, Fischer B, Foxcroft D, Humphreys K. Drug policy and the public good: evidence for effective interventions. Lancet 2012; 379: 71-83.
22. Becker GS, Murphy KM, Grossman M. The Market for Illegal Goods: The Case of Drugs. J Polit Econ 2006; 114(11): 38-60.
23. Briggs A. Handling Uncertainty in Economic Evaluation. BMJ 1999; 319(7202): 120.
24. Hodgson TA. The State of the Art of Cost-of-Illness Studies. Adv Health Econ Health Serv Res 1983; 4: 129-164.
25. Mascioli F, Rossi C. Capture-recapture methods to estimate prevalence indicators for the evaluation of drug policies. UNODC, Bulletin on Narcotics 2008; 110: 5-26.
26. Di Censi L, Esposito N, Scacciatelli D, Rossi C. Epidemiological indicators to evaluate drug supply policy and interventions: estimation of the dealer populations using routine administrative data. The case of Italy. Technical Report EUJustice-WS5, 1, CIBB 2012.
27. Reuter P, Trautmann F. A report on global illicit drugs markets 1998-2007.TrimbosIntstitute, Utrecht; 2009.
28. Degenhardt L, Hall W. Extent of illicit drug use and dependence, and heir contribution to the global burden of disease. Lancet 2012; 379: 55-70.
29. Room R, Reuter P. How well do international drug conventions protect public health? Lancet 2012; 379: 71-83.
30. Postma M. Public expenditure on drugs in the EU. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Luxemburg; 2004.
31. Reuter P, Ramstedt M, Rigter H. Developing a Framework for Estimating Government Drug Policy Expenditures. European Monitoring Centre for Drugs and Drug Addiction (emcdda), Lisbon, Portugal; 2004.